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Abstract To increase the cell adhesion activity of 74RGD4, an 
RGDS-inserted mutant between Va] 74 and Asn 7s of human ly- 
sozyme, one more site for the RGD introduction was investigated 
in the lysozyme molecule. We found that 47RGD4 with RGDS 
in place of AGDR (residues 47 to 50) in a/]-turn region possesses 
the same level of adhesion activity as that of 74RGD4. The 
acceptance of the RGD introduction in the l~-turn region of 
human lysozyme is in good agreement with recent studies on the 
functional conformation of RGD. We constructed (47,74)RGD4, 
a mutant containing RGD at two sites, by combining the N- 
terminal domain of 47RGD4 and the C-terminal domain of 
74RGD4. The (47,74)RGD4 lysozyme, with two functional RGD 
sequences, exhibits even higher cell adhesion activity than that of 
74RGD4 or 47RGD4. 
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I. Introduction 
The Arg-Gly-Asp (RGD) sequence is well-known as a site in 
cell adhesive proteins uch as fibronectin [1], vitronectin [2], and 
fibrinogen [3] for binding to their receptors, the integrins [4]. 
We previously constructed a mutant, 74RGD4, by inserting 
RGDS of human fibronectin between Val TM and Asn 75 in a 
flexible loop region of human lysozyme, using a yeast expres- 
sion system [5]. To increase the cell adhesion activity of the 
74RGD4 mutant, we constructed another mutant, Cys-RGD4, 
by inserting RGDS flanked by two Cys residues at the same site 
in the lysozyme molecule [6]. This design is based on the fact 
that the cyclic form of an RGD-containing peptide has much 
higher affinity to the integrins than the linear counterpart [7]. 
For both mutants, we have already reported the structural and 
functional analyses, and discussed the functional conformation 
of the RGD sequence [5,8]. 
In parallel with the construction of Cys-RGD4, we have tried 
another design to tailor the 74RGD4 mutant to possess higher 
adhesion activity. In this study, we have searched for one more 
RGD introduction site in the lysozyme molecule. Here we re- 
port the construction of (47,74)RGD4, a mutant lysozyme con- 
taining RGD at two sites, and its functional evaluation. The 
structural feature of the possible introduction site of RGD in 
human lysozyme is discussed, in connection with the functional 
conformation of RGD.  
*Corresponding author. Fax: (81) (6) 872 8210. 
Abbreviations." RGD, Arg-Gly-Asp; BHK, baby hamster kidney. 
2. Materials and methods 
2.1. Vector constructions 
Oligonucleotides were chemically synthesized using an automated 
DNA synthesizer (Model 380B, Applied Biosystems). The mutation 
was performed in M 13mp 19XhLZM using the site-directed mutagene- 
sis system Mutan-K (Takara Shuzo). The primer used for the con- 
struction of 47RGD4, for example, was 5'-AGTCTGTAGA- 
ACTGTCGCCACGGTTGTAATT-3'. The underlined bases indicate 
mismatches. The sequence of the mutated gene was confirmed by dide- 
oxy sequencing. The genes encoding the signal sequence and the mu- 
tated human lysozyme were combined with an XhoI- Sinai large frag- 
ment from pERI8602 [9] to construct the expression plasmid. 
The M13mpl9XhLZM plasmid possesses an XbaI restriction site 
between codons corresponding to Ser 61 and Arg 62 of human lysozyme 
[9]. To construct the (47,74)RGD4 expression plasmid, the following 
three fragments were combined: an XhoI-XbaI fragment encoding the 
signal sequence and the N-terminal domain of 47RGD4, an XbaI-SmaI 
fragment encoding the C-terminal domain of 74RGD4 [5], and an 
XhoI-SmaI large fragment from pERI8602. 
2.2. Expression and purification of mutant human lysozymes 
Mutant human lysozymes were expressed in yeast as described previ- 
ously [10]. Secreted mutant lysozymes were purified essentially as de- 
scribed [9]. HPLC was performed using a cation-exchange column 
(Asahipak ES-502C; Asahikasei, Japan) and a hydroxyapatite column 
(TAPS-020810, Tonen K.K., Japan). 
2.3. Measurement of activity 
Lytic activity was measured using Micrococcus lysodeikticus cells as 
a substrate [9]. Protein was determined by measuring the weight in the 
freeze-dried form of each mutant lysozyme. 
Cell adhesion activity was determined using baby hamster kidney 
(BHK) cells as described [6,11]. The amount of lysozyme adsorbed onto 
a plate was estimated by subtracting the unadsorbed amount from the 
added amount of lysozyme in the assay. The unadsorbed amount was 
determined based on the lytic activity remaining in the sample solution 
after binding to the plate. The results indicated that the adsorption 
efficiency was in the range of 60-80% at the concentrations shown in 
Fig. 2, for both native and mutant lysozymes. 
3. Results and discussion 
We previously constructed a cell adhesive protein, 74RGD4, 
by inserting the RGDS sequence between Val TM and Asn 75 in a 
long loop consisting of residues of Cys 65 to Cys 8~ in human 
lysozyme [5]. The backbone structure of the 74RGD4 lysozyme 
refined by X-ray crystallography is shown in Fig. 1. To find an 
RGD introduction site in a different region than the long loop 
of the lysozyme molecule, we tried to construct hree lysozyme 
variants by means of site-directed mutagenesis, namely 
14RGD4 with RGDS in place of RLGM (residues 14 to 17) in 
an a-helix, 41RGD4 with RGDS in place of RATN (residues 
41 to 44) in a fl-sheet, and 47RGD4 with RGDS in place of 
AGDR (residues 47 to 50) in a fl-turn. The 47RGD4 mutant 
was secreted with high efficiency in our yeast expression system 
(Table 1), while the 14RGD4 and 41RGD4 mutants failed to 
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Fig. 1. Stereo drawing of the backbone structure of the 74RGD4 ly- 
sozyme. The picture was produced with the program MOLSCRIPT [20] 
using the atomic oordinates of74RGD4 [5]. The a-helix and fl-strand 
parts are shown as a ribbon model. The RGD introduction sites in this 
study are labeled. 
be folded correctly, and were not secreted from the yeast cells. 
The lytic activity of 47RGD4 as well as 74RGD4 was nearly 
the same as that of the native form (Table 1), indicating that 
these RGD introductions had no effect on the active cleft of 
human lysozyme. The successful folding of these fully active 
mutants is probably due to the distant location of the introduc- 
tion sites from the active cleft [12]. 
Using baby hamster kidney (BHK) cells, 47RGD4 was 
shown to possess the same level of adhesion activity as that of 
74RGD4 (Fig. 2). We also produced another mutant, 
101RGD4, by substituting RGDS for RDPQ (residues 101 to 
104) in a turn-like region of the lysozyme molecule. In the cell 
adhesion assay, however, the 10tRGD4 mutant was inactive. 
This is probably because the RGD region of the 101RGD4 
lysozyme fails to have a fl-turn structure owing to the location 
in the bottom of a loop consisting of residues ofArg m~ to Val u° 
[12] (Fig. 1). On the other hand, the RGD sequence of the 
47RGD4 mutant is destined to assume a stable turn conforma- 
tion, since the two fl-strands, Ala42-Asn 46 and SerhLGly 55, con- 
nect by the RGDS (residues 47 to 50) to form a rigid fl-sheet 
(Fig. 1). Thus, these results suggest hat the introduction of a 
functional RGD sequence is acceptable only in a certain fl-turn 
region of human lysozyme. 
This structural information about the RGD introduction site 
is in good accordance with the experimental studies on the 
functional conformation of the RGD region in several proteins. 
We have recently solved the X-ray crystal structure of the 
Table 1 
Production and relative lytic activity of each mutant lysozyme 
Lysozyme Productivity a (mg/1) Relative lytic activity 
(%) 
Native 5.3 100 
74RGD4 6.3 109 
47RGD4 4.5 92 
(47,74)RGD4 6.7 83 
a Based on lyric activity in the culture supernatant. 
CRGDSC-inserted lysozyme, Cys-RGD4. The RGD sequence 
in this protein resides within a stable type II' fl-turn, with Gly 
and Asp in positions 2and 3 of the turn [8]. The fibronectin type 
III domain from human tenascin [13], and the leech protein 
decorsin [14] also have type II' fl-turn structures in their RGD 
regions. In addition, a flexible conformation of RGD has been 
reported in the 74RGD4 lysozyme [5], the tenth type III module 
of human fibronectin [15], and the disintegrins, a family of 
integrin antagonists from snake venoms [16,17]. In these cases, 
the RGD region, which is highly flexible by nature, could as- 
sume a rigid turn conformation when it binds to integrins to 
form a ligand-receptor complex. It is also possible to consider 
that the RGD region has a type II' fl-turn by itself, and that 
it was ill-defined because of its location at the apex of a flexible, 
long loop. 
We finally constructed (47,74)RGD4, a mutant containing 
RGD at two sites, by combining the N-terminal domain of 
47RGD4 and the C-terminal domain of 74RGD4, as described 
in section 2. The (47,74)RGD4 lysozyme was successfully se- 
creted with full lytic activity (Table 1). As shown in Fig. 2, the 
(47,74)RGD4 lysozyme xhibited even higher adhesion activity 
to BHK cells than that of 74RGD4 or 47RGD4. It was also 
confirmed that this activity is nearly equal to 10% of human 
vitronectin activity (Fig. 2). The difference might be reasonable, 
if we consider that the natural cell adhesive proteins including 
vitronectin, possess a second binding site besides the RGD 
region to exhibit the optimum affinity for the integrins [17 19]. 
The cell adhesion activities of the three mutants, 74RGD4, 
47RGD4, and (47,74)RGD4, were completely inhibited by the 
addition of either GRGDSP peptide or polyclonal antibody 
against vitronectin receptor, as was the case for the vitronectin 
activity (data not shown). The results indicate that the cell 
adhesion signals in these mutant lysozymes are transduced to 
BHK cells through the interaction with the vitronectin recep- 
tor, the integrin ~vfl3. 
The high cell adhesion activity of the (47,74)RGD4 mutant 
suggests that both of the introduced RGD sequences are func- 
tional. This speculation was further supported by additional 
experiments, in which each substitution of Glu for Asp in the 
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Fig. 2. Cell adhesion assay on the substrates coated with each mutant 
lysozyme. The plastic substrates were coated with different concentra- 
tions of vitronectin (o), native lysozyme (e), 74RGD4 (A), 47RGD4 
(A), and (47,74)RGD4 (D). BHK cells were incubated on the substrates 
for 60 min at 37°C in a CO2 incubator. The cell adhesion activity was 
expressed as the number of cells adhering to unit surface area (cm2). 
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two RGD-containing regions of (47,74)RGD4 results in a sig- 
nificant decrease in the cell adhesion activity (data not shown). 
In addition, adhesion activity in a mixture of 74RGD4/ 
47RGD4 (1:1) was similar to that of (47,74)RGD4, when ex- 
pressed against heir RGD concentrations (data not shown). 
These results suggest hat the higher activity of (47,74)RGD4 
is due to the increased concentration of the RGD sites, namely 
the additive effect of 74RGD4 and 47RGD4. 
We have reported the successful construction of 
(47,74)RGD4, a cell adhesive lysozyme with two functional 
RGD sequences, and discussed the structural feature of the 
possible introduction site of RGD in human lysozyme. Accord- 
ing to the model structure of the lysozyme molecule (Fig. 1), 
the two RGD introduction sites are located at a considerable 
distance (19.4 A). Thus, the (47,74)RGD4 mutant may be use- 
ful as a functional cross-linker in RGD-dependent cell-to-cell 
interactions, differently from 74RGD4 or 47RGD4. 
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